Alzamend Neuro Receives FDA "Study May Proceed" Notification for a Phase IIA Clinical Trial of AL001, a Next‑Generation Lithium Therapeutic Drug Candidate, in Post-Traumatic Stress Disorder Patients

Alzamend's recently completed Phase IIA study of AL001 in Alzheimer's patients and healthy subjects showed a benign safety profile and identified a candidate dose that is unlikely to require therapeutic drug